These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 796526)

  • 41. [Microcirculation and its correction in patients with diabetes mellitus].
    Petrova TR; Vil'chinskaia MN
    Klin Med (Mosk); 1983 Apr; 61(4):69-73. PubMed ID: 6865294
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapeutic results with xanthine derivatives in the intermittent claudication syndrome in diabetic patients].
    Gómez Reyes D; Rojas Hidalgo E
    Rev Clin Esp; 1988 Jan; 182(1):3-6. PubMed ID: 3375512
    [No Abstract]   [Full Text] [Related]  

  • 43. Diabetic microangiopathy in KK mice. IV. Effect of pyridinolcarbamate on kidney glucosyltransferase activity and glomerulosclerosis.
    Reddi AS; Oppermann W; Chen M; Camerini-Davalos RA
    Exp Mol Pathol; 1978 Oct; 29(2):149-55. PubMed ID: 689139
    [No Abstract]   [Full Text] [Related]  

  • 44. Attempts to delay progression in occlusive atherosclerosis.
    Terry EN; Rouen LR; Clasuss RH; Katz MC; Redisch W
    Ann N Y Acad Sci; 1976; 275():379-85. PubMed ID: 1070279
    [No Abstract]   [Full Text] [Related]  

  • 45. Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
    Reddi AS; Oppermann W; Velasco CA; Camerini-Davalos RA
    Exp Mol Pathol; 1977 Apr; 26(2):325-39. PubMed ID: 852540
    [No Abstract]   [Full Text] [Related]  

  • 46. [Principles of conservative treatment of peripheral circulation disorders in diabetics].
    Wüstenberg PW
    Z Arztl Fortbild (Jena); 1972 Jan; 66(2):65-70. PubMed ID: 4554715
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical experiences with pyridinolcarbamate in ophthalmology].
    Musini A; Fabbri G; Tancini G
    Ann Ottalmol Clin Ocul; 1969 Feb; 95(2):101-23. PubMed ID: 5398786
    [No Abstract]   [Full Text] [Related]  

  • 48. [Study of the action of a vascular protector on diabetic vascular fragility].
    Nove-Josserand G; Chirat P; Bussy L; Bonnamour C; Peaud PY; Ortonne JP; Gaillarde B; Plauchu M
    Lyon Med; 1971 Dec; 226(19):791-4. PubMed ID: 5159275
    [No Abstract]   [Full Text] [Related]  

  • 49. [Hydroxyproline indicators before and after treatment of diabetic angiopathies].
    Spesivtseva VG; Mamaeva GG; Starosel'tseva LK; Tulemisov EU; Bokaneva IA
    Ter Arkh; 1978; 50(1):93-7. PubMed ID: 635809
    [No Abstract]   [Full Text] [Related]  

  • 50. Pyridinolcarbamate in the long-term treatment of ischaemic heart disease.
    Gulyás A; Szám I
    Ther Hung; 1976; 24(2):63-6. PubMed ID: 982341
    [No Abstract]   [Full Text] [Related]  

  • 51. Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
    Orbetzova V; Jurukova Z; Orbetzova M
    Artery; 1980; 8(6):560-9. PubMed ID: 7259535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of prodectin and lipoic acid on the lipid metabolism indicators in chronic ischemic heart disease].
    Grigor'ian VA; Klantsa NA; Prishliak VD; Klantsa PN
    Vrach Delo; 1981 Oct; (10):13-5. PubMed ID: 6795820
    [No Abstract]   [Full Text] [Related]  

  • 53. [Diabetic macroangiopathy in Senegalese].
    Koaté P; Ndiaye IP; Diouf S; Sylla M; Diop G; Sarr M; Ba SA
    Ann Cardiol Angeiol (Paris); 1982 May; 31(3):235-40. PubMed ID: 7125568
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and metabolic profile in diabetic cardiovascular disease.
    Vaishnava H; Hagroo AA
    J Indian Med Assoc; 1973 Aug; 61(4):159-66. PubMed ID: 4590355
    [No Abstract]   [Full Text] [Related]  

  • 55. [Mechanism of action of the antikinin preparation pyridinolcarbamate on the development of experimental tuberculosis].
    Makinskiĭ AI; Solov'eva IP; Braude VI
    Probl Tuberk; 1984 May; (5):60-5. PubMed ID: 6739480
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of parmidine and drugs affecting kinin metabolism on pain reactions in mice].
    Shvarts GIa
    Farmakol Toksikol; 1981; 44(5):606-11. PubMed ID: 7308443
    [No Abstract]   [Full Text] [Related]  

  • 57. [Therapeutic activity of anti-platelet aggregation agents in arterial diseases].
    Delboy C; Jouve R; Escande M; Juhan I; Bouvenot G
    Sem Hop Ther; 1977 Nov; 53(9):431-40. PubMed ID: 341318
    [No Abstract]   [Full Text] [Related]  

  • 58. Preventing diabetic complications: a primary care perspective.
    Zimmet P
    Diabetes Res Clin Pract; 2009 May; 84(2):107-16. PubMed ID: 19278746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The effect of pyridinolcarbamate on the skin microcirculation in patients with severe skin necroses. A double-blind trial study].
    Fagrell B
    Vasa; 1976; 5(4):366-72. PubMed ID: 1007546
    [No Abstract]   [Full Text] [Related]  

  • 60. [Current status of diabetic microangiopathy].
    Mosora N; Hîncu N; Duţu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1977; 29(6):513-8. PubMed ID: 24247
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.